Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — Kepler Cheuvreux 19th German Corporate Conference 2020
43 slides from Fresenius SE & Co. KGaA's conference presentation, Jan 21, 2020
Slide 1: Kepler Cheuvreux 19th German Corporate Conference
Kepler Cheuvreux 19th German Corporate Conference Frankfurt, 21-22 January 2020 Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive
Slide 3: A Global Leader In Health Care Products And Services
A Global Leader In Health Care Products And Services ~€33.5 bn in Sales Global presence in (as of Dec. 31, 2018) 100+ countries Total Shareholder Return: 10-year CAGR: ~15% Strong portfolio 292,000+ employees of products (30% of sales) worldwide and services (70% of sales) (as of September 30, 2019)
Slide 4: Strong and Balanced Health Care Portfolio
Strong and Balanced Health Care Portfolio Ownership: ~31% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis Products Hospital Supplies Hospital Operation Projects and Services for Health Care Services Hospitals • Dialysis services • IV drugs • Acute care • Post-acute care • Hemodialysis produc
Slide 5: Total Shareholder Return – CAGR, Rounded
Total Shareholder Return – CAGR, Rounded 10 years 15 years 20 years 15% 14% 14% 13% 11% 10% 9% 8% 8% 8% 6% 3% DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 MSCI World Fresenius Fresenius Health Care Health Care Health Care Source: Bloomberg; divide
Slide 6: Fresenius Medical Care: Global Dialysis Market Leader
Fresenius Medical Care: Global Dialysis Market Leader • The world’s leading provider of dialysis products Market Dynamics and services treating more than 342,000 patients1 in 4,003 clinics1 Global Dialysis Market 2018: • Provide highest standard of product quality and • ~€71 bn • ~6% patient growth
Slide 7: Fresenius Kabi: A Leading Global Hospital Supplier
Fresenius Kabi: A Leading Global Hospital Supplier • Comprehensive product portfolio for critically and Market Dynamics chronically ill patients • Strong Emerging Markets presence Global Addressable Market 2018: • Leading market positions in four product • ~€81 bn segments Growth Drivers: Generic IV
Slide 8: Fresenius Helios: Europe's Largest Private Hospital Operator Helios Germany
Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Germany • ~5%1 share in German acute care hospital Market Dynamics market • Organic growth based on growing number of German Acute Care Hospital Market: admissions and reimbursement rate increases • ~€102 bn2 • Ranks as quality lead
Slide 9: Fresenius Helios: Europe's Largest Private Hospital Operator Helios Spain
Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Spain • ~€3.0 bn sales in 2018 Market Dynamics • ~12%1 share in Spanish private hospital market Spanish Private Hospital Market: • Market leader in size and quality with excellent • ~€14 bn2 growth prospects Growth Drivers: • Broad
Slide 10: Fresenius Vamed: Leading Global Hospital Projects and Services Specialist
Fresenius Vamed: Leading Global Hospital Projects and Services Specialist • Manages hospital construction/expansion Market Dynamics projects and provides services for health care facilities worldwide Growth Drivers: • Offers project development, planning, turnkey • Emerging Market demand for buildin
Slide 11: Capital deployment centers on sustainable long-term value creation
Fresenius Group: Capital deployment centers on sustainable long-term value creation Re-investments in Fuel organic growth with low-risk high- own business return investments Short-term focus on small bolt-on Strategic acquisitions; long-term rigorous pursuit of acquisitions inorganic growth trajecto
Slide 12: Healthy Growth Targets 2020 - 2023
Fresenius Group: Healthy Growth Targets 2020 - 2023 Growing Markets with High Marketing of existing Attractive markets Entry Barriers value chain Strengthening and Attractive Product Pipeline Market consolidation extension of value chain Entry into attractive Development of post- Synergies biosimila
Slide 13: Healthy Growth Targets 2020 – 2023 (CAGRs)
Fresenius Group: Healthy Growth Targets 2020 – 2023 (CAGRs) Organic sales growth 4 – 7% (plus ~1% small to mid- size acquisitions) Organic net income1 growth 5 – 9% (plus ~1% small to mid- size acquisitions) 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA Before special items Ke
Slide 14: Our Priorities: We Want To Be #1 For Our Patients, Employees And Shareholders
Our Priorities: We Want To Be #1 For Our Patients, Employees And Shareholders Serving the well-being Doing the right thing Being an attractive Protecting nature as Caring for of the patient employer the basis of life human rights • Quality of medical • Code of Conduct • Personnel structure • Water •
Slide 15: Financial Review Q3/19
Financial Review Q3/19 Kepler Cheuvreux 19th German Corporate Conference © Fresenius SE & Co. KGaA Investor Relations 15
Slide 16: Q3/19 Highlights
Q3/19 Highlights • Strong organic sales growth across all business segments • Growth investments proceeding according to plan • Fresenius Kabi: excellent growth in Emerging Markets partially offsets softer development in North America • Fresenius Helios showing excellent organic sales growth across
Slide 17: Fresenius Kabi: Update
Fresenius Kabi: Update North America • Increased competition for certain molecules • The opioid market has not recovered as anticipated • 31 Kabi-marketed IV drugs currently designated in shortage (vs. 36 at Q2/19) • Low to mid-single-digit price erosion in our base product portfolio • Product launc
Slide 18: Fresenius Helios: Update
Fresenius Helios: Update Helios Germany Investment initiatives • Employer of choice: Continued to attract meaningful number of nurses in Q3/19 • Vacant chief doctor positions now re-filled • Good progress with transformation of MVZs (“outpatient centers”) within new business line Outpatient Services
Slide 19: Fresenius Helios: Update (Spain)
Fresenius Helios: Update Helios Spain Expansion in Spain Expansion in Latin America • Opening of two new outpatient centers in • Acquisition of two additional hospitals the cities of Toledo and Algeciras in Colombia • Acquisition of plot in the metropolitan • ~€50 million of sales area of Barcelona
Slide 20: Group: Q3/19 Key Financials
Fresenius Group: Q3/19 Key Financials €m Q3/191 IFRS 16 special Q3/19 Δ YoY cc1,2 effect items reported Sales 8,877 -35 - 8,842 6% EBIT 1,130 23 -24 1,129 -1% Net interest -124 -47 -1 -172 15% Income taxes -232 5 25 -202 -10% Net income3 453 -8 -1 444 0% Balance sheet total 61,092 5,667 - 66,759 Ope
Slide 21: Group: Q3/19 Business Segment Growth
Fresenius Group: Q3/19 Business Segment Growth Organic sales growth1 EBIT growth (cc)1 +5% -3% +5% +1% +6% -10% +17% +10% +5% -1% 1 On a comparable basis: Q3/18 adjusted for divestitures of Care Coordination activities at FMC; Q3/19 adjusted for IFRS 16 effect. All figures before special items Keple
Slide 22: Fresenius Kabi: Q3/19 Regional Highlights (1/2)
Fresenius Kabi: Q3/19 Regional Highlights (1/2) North America Europe • -4% organic growth • 4% organic growth • Increasingly intense competitive • Strong growth of enteral nutrition environment for certain molecules business • Further easing of shortage tailwinds • Confirm FY/19 outlook: Low to mid-
Slide 23: Fresenius Kabi: Q3/19 Regional Highlights (2/2)
Fresenius Kabi: Q3/19 Regional Highlights (2/2) Emerging Markets China: • 18% organic sales growth • Continued positive momentum Asia-Pacific ex China: • 19% organic sales growth Latin America/Africa: Total Emerging Markets • 16% organic sales growth Confirm FY/19 outlook: Clearly double-digit organ
Slide 24: Fresenius Kabi: Q3 & Q1-3/19 EBIT Growth
Fresenius Kabi: Q3 & Q1-3/19 EBIT Growth €m Q3/19 Δ YoY cc Q1-3/19 Δ YoY cc North America 225 -8% 703 -2% Margin 36.3% -180 bps 38.7% 20 bps Europe 75 -11% 241 -6% Margin 13.3% -230 bps 14.1% -150 bps Asia-Pacific/Latin 135 34% 352 24% America/Africa Margin 23.4% 330 bps 21.6% 200 bps Corporate and
Slide 25: Fresenius Helios: Q3/19 Highlights
Fresenius Helios: Q3/19 Highlights Helios Germany Helios Spain • Strong organic sales growth of 5%; positive • Healthy organic sales growth of 9%; admissions development decline in admissions during hot summer months not as pronounced as in prior year • Sales growth supported by reclassification of
Slide 26: Fresenius Helios: Q3 & Q1-3/19 Key Financials
Fresenius Helios: Q3 & Q1-3/19 Key Financials €m Q3/19 Δ YoY Q1-3/19 Δ YoY Total sales 2,230 7% 6,890 2%/5%1 Thereof Helios Germany 1,474 5% 4,465 -1%/4%1 Thereof Helios Spain 757 12% 2,425 9% Total EBIT2 183 -10% 723 -7%/-5%1 Margin 8.2% -160 bps 10.5% -100 bps Thereof Helios Germany 130 -9% 433 -1
Slide 27: Fresenius Vamed
Fresenius Vamed • Strong Q3/19 with 17% organic sales €m Q3/19 Δ YoY Q1-3/19 Δ YoY growth Total sales 562 18% 1,469 48% • Both, service business and project Thereof organic sales 17% 24%1 business contributed to strong growth in Q3/19 Service business 349 11% 1,025 60% 29%1 Project business 213 32%
Slide 28: Group: Cash Flow
Fresenius Group: Cash Flow Operating CF1 Capex (net) Free Cash Flow1,2 €m Q3/19 LTM Margin Q3/19 LTM Margin Q3/19 LTM Margin 362 13.4% -179 -10.0% 183 3.4% 183 7.0% -90 -4.7% 93 2.3%3 27 3.2% -10 -1.6% 17 1.6% Corporate/Other 11 n.a. -13 n.a. -2 n.a. Excl. FMC 583 9.5%4 -292 -6.9% 291 2.6%4 1,298 10
Slide 29: Group: 2019 Financial Outlook by Business Segment
Fresenius Group: 2019 Financial Outlook by Business Segment FY/18 Q1-3/19 FY/191 €m (except otherwise stated) Base Actual1 FY/19e1 New Sales growth (org) 6,544 4% 3% - 6% EBIT growth (cc) 1,1392 4% 3% - 6% Sales growth (org) 8,993 5% 2% - 5% EBIT growth 1,052 -7% -5% to -2% Sales growth (org) 1,688
Slide 30: Group: 2019 Financial Guidance
Fresenius Group: 2019 Financial Guidance €m FY/18 Q1-3/19 FY/19e2 (except otherwise stated) Base1 Actual2 FY/19e2 New Sales growth 33,009 6% 4% - 7% (cc) Net income3 1,872 0% ~0% growth (cc) 1 Before special items and after adjustments 2 Excluding transaction-related expenses, revaluations of biosim
Slide 31: Attachments
Attachments Kepler Cheuvreux 19th German Corporate Conference © Fresenius SE & Co. KGaA Investor Relations 31
Slide 32: Group: Leverage Ratio
Fresenius Group: Leverage Ratio Net Debt/EBITDA target 2019 4,00 4.0 Around the upper-end of self-imposed target 3.5 3,50 corridor of 2.5 – 3.0 x3 2 3.22 3.21 2 2 3.13 3.09 2.98 3,00 3.0 2.84 2.80 2.75 2.67 2.71 2.65 2.55 2.53 2,50 2.5 2.33 2,00 1 2011 2012 2013 2014 2015 2016 2017 Q1 Q2 Q3 Q4 Q1 Q2
Slide 33: Fresenius Kabi: Organic Sales Growth by Regions
Fresenius Kabi: Organic Sales Growth by Regions Δ YoY Δ YoY €m Q3/19 organic Q1-3/19 organic North America 619 -4% 1,815 -3% Europe 564 4% 1,709 3% Asia-Pacific/Latin 578 17% 1,629 15% America/Africa Asia-Pacific 406 18% 1,121 15% Latin America/Africa 172 16% 508 16% Total sales 1,761 5% 5,153 4% Ke
Slide 34: Fresenius Kabi: Organic Sales Growth by Product Segment
Fresenius Kabi: Organic Sales Growth by Product Segment Δ YoY Δ YoY €m Q3/19 organic Q1-3/19 organic IV Drugs 746 -2% 2,202 -1% Infusion Therapy 208 7% 621 3% Clinical Nutrition 492 10% 1,416 9% Medical Devices/ 315 14% 914 11% Transfusion Technology Total sales 1,761 5% 5,153 4% Kepler Cheuvreux 19
Slide 35: Fresenius Helios: Key Metrics
Fresenius Helios: Key Metrics Q1-3/19 FY/18 Δ No. of hospitals Helios Germany 86 86 0% - Acute care hospitals 83 83 0% No. of hospitals Helios Spain 50 47 6% (Hospitals) No. of beds Helios Germany 28,934 29,329 -1% - Acute care hospitals 28,407 28,802 -1% No. of beds Helios Spain 7,126 7,019 2% (Hos
Slide 36: Attachments
Attachments Kepler Cheuvreux 19th German Corporate Conference © Fresenius SE & Co. KGaA Investor Relations 36
Slide 37: FY/18 base for Fresenius Group Guidance FY/19
FY/18 base for Fresenius Group Guidance FY/19 €m Sales reported 33,530 Divestitures of Care Coordination activities at FMC (H1/18) -521 Sales basis for growth rates 33,009 Net income reported 2,027 Transaction Costs, Akorn, Biosimilars 25 Bridge Financing Costs Akorn 12 Revaluations of Biosimilars c
Slide 38: FY/18 base for Fresenius Medical Care Outlook FY/19
FY/18 base for Fresenius Medical Care Outlook FY/19 €m Sales reported 16,547 Divestitures of Care Coordination activities at FMC (H1/18) -521 Sales basis for growth rates 16,026 Net income reported 1,982 Impact of FCPA related charge 28 Gain related to divestitures of Care Coordination activities -6
Slide 39: FY/18 base for Fresenius Kabi Outlook FY/19
FY/18 base for Fresenius Kabi Outlook FY/19 €m Sales basis for growth rates 6,544 Transaction Costs Akorn, Biosimilars 34 Revaluations of Biosimilars contingent liabililties 7 EBIT (before special items = base for Kabi guidance) 1,139 The special items are reported in the Group Corporate/Other segme
Slide 40: IFRS 16: Profit and Loss - Implications
IFRS 16: Profit and Loss - Implications €m Expected IFRS 16 effect on 2019 Sales - ~€0.1 bn (discontinuation of sale-leaseback transactions at FMC NA) EBITDA + ~€1.0 bn (fewer rent expenses) Depreciation and amortization - ~€0.9 bn (additional depreciation) EBIT + ~€0.1 bn Interest - ~€0.2 bn (addit
Slide 41: IFRS 16: Balance Sheet
IFRS 16: Balance Sheet €m Expected IFRS 16 effect on 2019 Right-of-use-asset ~€5.2 bn Lease liability ~€5.5 bn Equity ~-€0.3 bn Leverage + ~30-40 bps Leases have to be recognized as a right-of-use-asset and corresponding liability Kepler Cheuvreux 19th German Corporate Conference © Fresenius SE & Co
Slide 42: 26th Consecutive Dividend Increase
Fresenius Group: 26th Consecutive Dividend Increase CAGR +16% 0.75 0.80 0.62 0.55 0.32 0.37 0.42 0.44 € 0.29 0.23 0.25 0.22 0.19 0.16 0.02 '93 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 '18 Dividend growth aligned to EPS growth Pay-out ratio: 24% Kepler Cheuvreux 19th German Corporate Confe
Slide 43: Financial Calendar / Contact
Financial Calendar / Contact Financial Calendar 20 February 2020 Results FY/19 06 May 2020 Results Q1/20 20 May 2020 Annual General Meeting 30 July 2020 Results Q2/20 29 October 2020 Results Q3/20 Please note that these dates could be subject to change. Contact Investor Relations Fresenius SE & Co.
Fresenius SE & Co. KGaA — Kepler Cheuvreux 19th German Corporate Conference 2020 on 6ix